Exemestane
Aromasin, Exemestane (exemestane) is a small molecule pharmaceutical. Exemestane was first approved as Aromasin on 1999-10-21. It is used to treat breast neoplasms in the USA. The pharmaceutical is active against aromatase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Aromasin, Exemestane (discontinued: Exemestane)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aromasin | New Drug Application | 2025-01-24 |
| exemestane | ANDA | 2025-08-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| breast neoplasms | EFO_0003869 | D001943 | C50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| S0156 | Exemestane, 25 mg |
Clinical
Clinical Trials
374 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 34 | 160 | 93 | 13 | 65 | 349 |
| Neoplasms | D009369 | — | C80 | 6 | 7 | 4 | 1 | 1 | 18 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | 11 | 3 | 1 | — | 16 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 3 | 3 | 1 | 1 | 8 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | 1 | 1 | 3 | 5 |
| Arthralgia | D018771 | — | M25.5 | — | — | — | 1 | 3 | 4 |
| Postmenopause | D017698 | — | — | — | 2 | — | 1 | 1 | 4 |
| Invasive hydatidiform mole | D002820 | — | D39.2 | 1 | — | 1 | 1 | 1 | 4 |
| Breast carcinoma in situ | D000071960 | — | D05 | — | 1 | 1 | 1 | — | 3 |
| Musculoskeletal pain | D059352 | — | — | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Male breast neoplasms | D018567 | — | — | 2 | 4 | 6 | — | 3 | 15 |
| Recurrence | D012008 | — | — | — | 6 | 3 | — | 1 | 10 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 3 | 1 | — | — | 4 |
| Intraductal carcinoma noninfiltrating | D002285 | — | D05.1 | 1 | 1 | 1 | — | 1 | 4 |
| Neoadjuvant therapy | D020360 | — | — | — | 2 | 2 | — | — | 4 |
| Ovarian epithelial carcinoma | D000077216 | — | — | — | 2 | 1 | — | — | 3 |
| Disease progression | D018450 | — | — | — | 1 | 1 | — | 1 | 3 |
| Stomatitis | D013280 | EFO_1001904 | K12.1 | — | 1 | 1 | — | — | 2 |
| Fatigue | D005221 | — | R53.83 | — | — | 1 | — | 1 | 2 |
| Sleep wake disorders | D012893 | — | G47 | — | — | 1 | — | 1 | 2 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 2 | 4 | — | — | — | 6 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 2 | 3 | — | — | — | 4 |
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | 1 | — | — | — | 3 |
| Lung neoplasms | D008175 | — | C34.90 | 2 | 1 | — | — | — | 3 |
| Breast diseases | D001941 | — | N60-N65 | 1 | 3 | — | — | — | 3 |
| Sarcoma | D012509 | — | — | — | 2 | — | — | — | 2 |
| Prostatic neoplasms | D011471 | — | C61 | — | 2 | — | — | — | 2 |
| Urologic neoplasms | D014571 | — | C64-C68 | — | 1 | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | — | — | — | 1 |
| Transitional cell carcinoma | D002295 | — | — | — | 1 | — | — | — | 1 |
Show 19 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | 2 | 3 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | — | — | — | — | 1 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 1 | — | — | — | — | 1 |
| Acrocephalosyndactylia | D000168 | EFO_0004123 | Q87.0 | 1 | — | — | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Carcinoma in situ | D002278 | — | D09.9 | 1 | — | — | — | — | 1 |
| Ductal carcinoma | D044584 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 2 | 2 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | — | — | — | 1 | 1 |
| Interstitial lung diseases | D017563 | EFO_0004244 | J84.9 | — | — | — | — | 1 | 1 |
| Pregnancy rate | D018873 | — | — | — | — | — | — | 1 | 1 |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | — | — | — | 1 | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Nutrition disorders | D009748 | EFO_0001069 | — | — | — | — | — | 1 | 1 |
| Periodontal diseases | D010510 | — | K05.6 | — | — | — | — | 1 | 1 |
| Xerostomia | D014987 | — | K11.7 | — | — | — | — | 1 | 1 |
| Hot flashes | D019584 | — | — | — | — | — | — | 1 | 1 |
Show 5 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Exemestane |
| INN | exemestane |
| Description | Exemestane is a 17-oxo steroid that is androsta-1,4-diene-3,17-dione in which the hydrogens at position 6 are replaced by a double bond to a methylene group. A selective inhibitor of the aromatase (oestrogen synthase) system, it is used in the treatment of advanced breast cancer. It has a role as an EC 1.14.14.14 (aromatase) inhibitor, an antineoplastic agent, an environmental contaminant and a xenobiotic. It is a 17-oxo steroid and a 3-oxo-Delta(1),Delta(4)-steroid. It derives from a hydride of an androstane. |
| Classification | Small molecule |
| Drug class | antineoplastics (aromatase inhibitors) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12 |
Identifiers
| PDB | — |
| CAS-ID | 107868-30-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200374 |
| ChEBI ID | 4953 |
| PubChem CID | 60198 |
| DrugBank | DB00990 |
| UNII ID | NY22HMQ4BX (ChemIDplus, GSRS) |
Target
Agency Approved
CYP19A1
CYP19A1
Organism
Homo sapiens
Gene name
CYP19A1
Gene synonyms
ARO1, CYAR, CYP19
NCBI Gene ID
Protein name
aromatase
Protein synonyms
CYPXIX, Cytochrome P-450AROM, Cytochrome P450 19A1, cytochrome P450, family 19, subfamily A, polypeptide 1, cytochrome P450, subfamily XIX (aromatization of androgens), Estrogen synthase, estrogen synthetase, flavoprotein-linked monooxygenase, microsomal monooxygenase
Uniprot ID
Mouse ortholog
Cyp19a1 (13075)
aromatase (P28649)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Aromasin – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Exemestane
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,551 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
14,828 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use